Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Boston Scientific (BSX) PT Raised to $36 at RBC Capital Ahead of 2Q Release
July 23, 2018 8:05 AM EDTRBC Capital raised its price target on Boston Scientific (NYSE: BSX) to $36.00 (from $32.00) while maintaining a Top Pick rating ahead of the company's 2Q earnings report. Analyst Glenn Novarro forecasts WW revenues of $2.45B and EPS of $0.34 for 2Q (consensus: $2.5B and $0.34). Novarro... More
